Multifunctional mesoporous silica nanoparticles mediated co-delivery of paclitaxel and tetrandrine for overcoming multidrug resistance

Jia, Lejiao; Li, Zhenyu; Shen, Jingyi; Zheng, Dandan; Tian, Xiaona; Guo, Hejian; Chang, Ping

doi:10.1016/j.ijpharm.2015.05.010

Cited by 84 publications

(49 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 It reported that MCF-7/ADR cells, a typical resistant cancer cell line of DOX, exhibit a cross drug resistant to PTX. 49,50 This cell line has been used to study the reversal of MDR for PTX in this study. Figure 12A revealed that the cell viability of taxol in MCF-7/ADR cells were above that in MCF-7 cells at each dose, suggesting a drug-resistant property against PTX.…”

Section: In Vitro Cytotoxicitymentioning

confidence: 99%

pH-triggered surface charge-switchable polymer micelles for the co-delivery of paclitaxel/disulfiram and overcoming multidrug resistance in cancer

Huo¹,

Zhu²,

Niu³

et al. 2017

IJN

View full text Add to dashboard Cite

Multidrug resistance (MDR) remains a major challenge for providing effective chemotherapy for many cancer patients. To address this issue, we report an intelligent polymer-based drug co-delivery system which could enhance and accelerate cellular uptake and reverse MDR. The nanodrug delivery systems were constructed by encapsulating disulfiram (DSF), a P-glyco-protein (P-gp) inhibitor, into the hydrophobic core of poly(ethylene glycol)- block -poly( l -lysine) (PEG- b -PLL) block copolymer micelles, as well as 2,3-dimethylmaleic anhydride (DMA) and paclitaxel (PTX) were grafted on the side chain of l -lysine simultaneously. The surface charge of the drug-loaded micelles represents as negative in plasma (pH 7.4), which is helpful to prolong the circulation time, and in a weak acid environment of tumor tissue (pH 6.5–6.8) it can be reversed to positive, which is in favor of their entering into the cancer cells. In addition, the carrier could release DSF and PTX successively inside cells. The results of in vitro studies show that, compared to the control group, the DSF and PTX co-loaded micelles with charge reversal exhibits more effective cellular uptake and significantly increased cytotoxicity of PTX to MCF-7/ADR cells which may be due to the inhibitory effect of DSF on the efflux function of P-gp. Accordingly, such a smart pH-sensitive nanosystem, in our opinion, possesses significant potential to achieve combinational drug delivery and overcome drug resistance in cancer therapy.

show abstract

Section: In Vitro Cytotoxicitymentioning

confidence: 99%

pH-triggered surface charge-switchable polymer micelles for the co-delivery of paclitaxel/disulfiram and overcoming multidrug resistance in cancer

Huo¹,

Zhu²,

Niu³

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…Therefore, efforts have been devoted to design multifunctional nano carriers aims to overcome these physiological obstacles (193). Among different nanocarriers, silica based nano-carriers are very attractive delivering the drug into selective sites (194), intracellular co-delivery of the drug and other therapeutic molecules such as genes (174) chemosensitisers (195) and peptides (193).…”

Section: Future Perspectivesmentioning

confidence: 99%

“…Multifunctional MSNs were utilised for intracellular co-delivery of therapeutic molecules with a great efficacy for enhancing the anticancer cytotoxicity and minimizing the multidrug resistance (156,157,193,195). Multidrug resistance (MDR) is the resistance of tumor cells to the chemotherapy where cancerous cells become resistant to different types of drugs simultaneously.…”

Section: Future Perspectivesmentioning

confidence: 99%

“…Multidrug resistance (MDR) is the resistance of tumor cells to the chemotherapy where cancerous cells become resistant to different types of drugs simultaneously. MDR causes the most challenges for scientists to develop efficient chemotherapeutic treatment for the tumors (195). MDR is multifactorial and can be classified into two main mechanisms; pump resistance (caused by certain membrane-bound proteins that form efflux pumps) and non-pump resistance (caused by activation of cellular antiapoptotic proteins).…”

Section: Future Perspectivesmentioning

confidence: 99%

See 1 more Smart Citation

Porous Inorganic Drug Delivery Systems—a Review

et al. 2017

View full text Add to dashboard Cite

Innovative methods and materials have been developed to overcome limitations associated with current drug delivery systems. Significant developments have led to the use of a variety of materials (as excipients) such as inorganic and metallic structures; marking a transition from conventional polymers. Inorganic materials, especially those possessing significant porosity, are emerging as good candidates for the delivery of a range of drugs (anti-biotics, anti-cancer and anti-inflammatories), providing several advantages in formulation and engineering (encapsulation of drug in amorphous form, controlled delivery and improved targeting). This review focuses on key selected developments in porous drug delivery systems. The review provides a short broad overview of porous polymeric materials for drug delivery before focusing on porous inorganic materials (e.g. Santa Barbara Amorphous (SBA) and Mobil Composition of Matter (MCM)) and their utilisation in drug dosage form development. Methods for their preparation and drug loading thereafter are detailed. Several examples of porous inorganic materials, drugs used and outcomes are discussed providing the reader with an understanding of advances in the field and realistic opportunities.

show abstract

“…Hyaluronic acid-decorated PLGA nanoparticles Breast cancer, squamous cell carcinoma [19] Paclitaxel and etoposide PEG-PLGA nanoparticles Osteosarcoma [20] Cisplatin and paclitaxel Folic acid modified PEG-PLGA nanoparticles Non-small lung cancer [21,22] Cisplatin and doxorubicin Transferrin modified PEG-PLGA nanoparticles Human hepatoma carcinoma [23] Combretastatin-A4 phosphate and doxorubicin mPEG-PLA nanoparticles Human nasopharyngeal epidermal carcinoma [24] Paclitaxel and tetrandrine CTAB@MSN Breast cancer [25] mPEG-PCL nanoparticles Gastric cancer [27] PEG-b-PCL nanoparticles Gastric cancer [28] Pirarubicin and paclitaxel Human serum albumin nanoparticles Breast cancer [15] Hypocrellin B and paclitaxel Hyaluronic acid-ceramide nanoparticles Lung cancer [29] Doxorubicin and paclitaxel mPEsG-b-PLG-b-PLL/DOCA nanovehicle Non-small cell lung cancer [30] PEG-PLGA and PEG-PLA nanoparticles have also been chemically altered to improve tumor targeting. For example, He et al [21,22] utilized folic acid (FA)-modified PEG-PLGA nanoparticles for the co-delivery of cisplatin (CDDP) and PTX.…”

Section: Docetaxel and Tanespimycinmentioning

confidence: 99%

Nanomedicine-Mediated Combination Drug Therapy in Tumor

Chen¹,

Xie²,

Sun³

et al. 2017

PHARMSCI

View full text Add to dashboard Cite

Background:Combined chemotherapy has gradually become one of the conventional methods of cancer treatment due to the limitation of monotherapy. However, combined chemotherapy has several drawbacks that may lead to treatment failure because drug synergy cannot be guaranteed, achievement of the optimal synergistic drug ratio is difficult, and drug uptake into the tumor is inconsistent. Nanomedicine can be a safe and effective form of drug delivery, which may address the problems associated with combination chemotherapy. Objective:This review summarizes the recent research in this area, including the use of nanoparticles, liposomes, lipid-polymer hybrid nanoparticles, and polymeric micelles, and provides new approach for combined chemotherapy. Methods:By collecting and referring to the related literature in recent years. Results:Compared with conventional drugs, nanomedicine has the following advantages: it increases bioavailability of poorly soluble drugs, prolongs drug circulation time in vivo, and permits multiple drug loading, all of which could improve drug efficacy and reduce toxicity. Furthermore, nanomedicine can maintain the synergistic ratio of the drugs; deliver the drugs to the tumor at the same time, such that two or more drugs of tumor treatment achieve synchronization in time and space; and alter the pharmacokinetics and distribution profile in vivo such that these are dependent on nanocarrier properties (rather than being dependent on the drugs themselves). Conclusion:Therefore, nanomedicine-mediated combination drug therapy is promising in the treatment of tumors.

show abstract

Multifunctional mesoporous silica nanoparticles mediated co-delivery of paclitaxel and tetrandrine for overcoming multidrug resistance

Cited by 84 publications

References 43 publications

pH-triggered surface charge-switchable polymer micelles for the co-delivery of paclitaxel/disulfiram and overcoming multidrug resistance in cancer

pH-triggered surface charge-switchable polymer micelles for the co-delivery of paclitaxel/disulfiram and overcoming multidrug resistance in cancer

Porous Inorganic Drug Delivery Systems—a Review

Nanomedicine-Mediated Combination Drug Therapy in Tumor

Contact Info

Product

Resources

About